Abstract
Left atrial appendage closure has emerged as a feasible stroke prevention strategy in selected patients with nonvalvular atrial fibrillation. Since its commercial approval in the United States in 2015, the use of percutaneous left atrial appendage closure has witnessed a substantial growth. However, certain issues remain unresolved with the technology. Knowledge of these issues, their significance, and the current and future efforts to resolve them is key for proper informed decision making by physicians and patients.
Original language | English (US) |
---|---|
Pages (from-to) | 2244-2248 |
Number of pages | 5 |
Journal | Mayo Clinic proceedings |
Volume | 95 |
Issue number | 10 |
DOIs | |
State | Published - Oct 2020 |
ASJC Scopus subject areas
- Medicine(all)